We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Randomized double-blind placebo-controlled trial of peptide T for HIV-associated cognitive impairment.
- Authors
Heseltine, P N; Goodkin, K; Atkinson, J H; Vitiello, B; Rochon, J; Heaton, R K; Eaton, E M; Wilkie, F L; Sobel, E; Brown, S J; Feaster, D; Schneider, L; Goldschmidts, W L; Stover, E S
- Abstract
Cognitive impairment is a common consequence of human immunodeficiency virus (HIV) infection, and dementia is one of the diseases that defines the acquired immunodeficiency syndrome. Peptide T (d-ala-peptide-T-amide) has been reported to block the binding of gp120 to brain tissue and to protect neurons from the toxic effects of gp120 in vitro. In pilot studies, administration of peptide T to HIV-positive patients with cognitive impairment was associated with improvement in cognition and constitutional symptoms.
- Publication
Archives of neurology, 1998, Vol 55, Issue 1, p41
- ISSN
0003-9942
- Publication type
Journal Article
- DOI
10.1001/archneur.55.1.41